67 related articles for article (PubMed ID: 27609042)
1. Article retraction. Sato Y, Honda Y, Iwamoto J, Amano N. Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease. J Musculoskelet Neuronal Interact 2013;13:346-52.
J Musculoskelet Neuronal Interact; 2016 Sep; 16(3):264. PubMed ID: 27609042
[No Abstract] [Full Text] [Related]
2. Articles retraction.
J Musculoskelet Neuronal Interact; 2018 Jun; 18(2):280. PubMed ID: 29855452
[TBL] [Abstract][Full Text] [Related]
3. Retraction: 'Sunlight exposure is important for preventing hip fractures in patients with Alzheimer's disease, Parkinson's disease, or stroke' by J. Iwamoto, T. Takeda and H. Matsumoto.
Acta Neurol Scand; 2018 Jun; 137(6):630. PubMed ID: 29732540
[TBL] [Abstract][Full Text] [Related]
4. RETRACTION.
Kurume Med J; 2016; 63(1.2):49. PubMed ID: 28408729
[TBL] [Abstract][Full Text] [Related]
5. Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Sato Y; Honda Y; Iwamoto J; Amano N
J Musculoskelet Neuronal Interact; 2013 Sep; 13(3):346-52. PubMed ID: 23989256
[TBL] [Abstract][Full Text] [Related]
6. Retraction: 'Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients,' by Sato Y., Honda Y., Iwamoto, J., Kanoko, T., and Satoh, K.
Mov Disord; 2019 Jan; 34(1):156. PubMed ID: 30653727
[No Abstract] [Full Text] [Related]
7. Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742.
Bauchner H; Redberg RF
JAMA Intern Med; 2016 Sep; 176(9):1256. PubMed ID: 27258431
[No Abstract] [Full Text] [Related]
8. Statement of Concern Regarding: Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a Predictive Factor for Hip Fracture in Elderly Women with Parkinson's Disease. Am J Med. 2005;118:1250-1255.
Alpert JS
Am J Med; 2018 Mar; 131(3):e109. PubMed ID: 29454423
[No Abstract] [Full Text] [Related]
9. Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Amagase K; Inaba A; Senta T; Ishikawa Y; Nukui K; Murakami T; Takeuchi K
J Physiol Pharmacol; 2011 Dec; 62(6):609-18. PubMed ID: 22314563
[TBL] [Abstract][Full Text] [Related]
10. Retraction: Paper "Comparison of the Effect of Vitamin K2 and Risedronate on Trabecular Bone in Glucocorticoid-Treated Rats: A Bone Histomorphometry Study" by Iwamoto J, et al. [Yonsei Med J 2009;50(2):189-194].
Yonsei Med J; 2018 Jan; 59(1):168. PubMed ID: 29214795
[TBL] [Abstract][Full Text] [Related]
11. Notice of Retraction: Sato Y, et al. Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke. Arch Intern Med. 2005;165(15):1743-1748.
Bauchner H; Redberg RF
JAMA Intern Med; 2016 Sep; 176(9):1256. PubMed ID: 27258587
[No Abstract] [Full Text] [Related]
12. Retraction Note: Three-year Experience with Alendronate Treatment in Postmenopausal Osteoporotic Japanese Women with or without Renal Dysfunction: A Retrospective Study.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Drugs Aging; 2019 Oct; 36(10):979. PubMed ID: 31418156
[TBL] [Abstract][Full Text] [Related]
13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
14. Retraction Statement.
Eur Neurol; 2018; 79(3-4):229. PubMed ID: 31344700
[TBL] [Abstract][Full Text] [Related]
15. Retraction: 'Beneficial Effect of Intermittent Cyclical Etidronate Therapy in Hemiplegic Patients Following an Acute Stroke' by Y. Sato, T. Asoh, M. Kaji and K. Oizumi.
J Bone Miner Res; 2016 Oct; 31(10):1911. PubMed ID: 27759930
[TBL] [Abstract][Full Text] [Related]
16. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Kushida K; Fukunaga M; Kishimoto H; Shiraki M; Itabashi A; Inoue T; Kaneda K; Morii H; Nawata H; Yamamoto K; Ohashi Y; Orimo H
J Bone Miner Metab; 2004; 22(5):469-78. PubMed ID: 15316868
[TBL] [Abstract][Full Text] [Related]
17. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
18. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Heaney RP; Zizic TM; Fogelman I; Olszynski WP; Geusens P; Kasibhatla C; Alsayed N; Isaia G; Davie MW; Chesnut CH
Osteoporos Int; 2002; 13(6):501-5. PubMed ID: 12107665
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
20. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
